|
121 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2334 News |
|
| «12...1718192021222324252627...4647» |
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=380, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=520 --> 380
- ||| Trial completion: Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=80, Completed, Sponsor: University of Sao Paulo General Hospital
N=520 --> 380 Recruiting --> Completed
- || Trial primary completion date: COGHIC-AV45: Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=70, Recruiting, Sponsor: University Hospital, Toulouse
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Jan 2015
- Tasigna (nilotinib) / Novartis, Inhibikase
New P1 trial: Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 (clinicaltrials.gov) - Nov 3, 2014
P1, N=36, Not yet recruiting, Sponsor: Georgetown University
- Trial completion, Enrollment change: Hereditary Deficits in Auditory Processing Leading to Language Impairment (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=875, Completed, Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)
Trial primary completion date: Dec 2013 --> Jan 2015 Recruiting --> Completed | N=1200 --> 875
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
New P3 trial: Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder (clinicaltrials.gov) - Oct 31, 2014
P3, N=150, Recruiting, Sponsor: H. Lundbeck A/S
- New P2 trial: ATP in Alzheimer Disease (clinicaltrials.gov) - Oct 31, 2014
P2, N=20, Not yet recruiting, Sponsor: Sara Varea
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
New P3 trial: Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder (clinicaltrials.gov) - Oct 31, 2014
P3, N=150, Recruiting, Sponsor: H. Lundbeck A/S
- Enrollment closed: END-DSD: Early Nurse Detection and Management of Delirium (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=390, Active, not recruiting, Sponsor: Penn State University
Recruiting --> Completed | N=1200 --> 875 Recruiting --> Active, not recruiting
- Trial completion: Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=6, Completed, Sponsor: University of Manitoba
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Enrollment change: Meditation or Education for Alzheimer Caregivers (clinicaltrials.gov) - Oct 30, 2014
P2, N=72, Completed, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=108 --> 72
- Trial completion, Enrollment change: Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients (clinicaltrials.gov) - Oct 30, 2014
P1, N=111, Completed, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed | N=108 --> 72 Active, not recruiting --> Completed | N=40 --> 111
- Trial primary completion date: Volunteers Adding Life in Dementia: VALID (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=120, Recruiting, Sponsor: Queen's University
Active, not recruiting --> Completed | N=40 --> 111 Trial primary completion date: Dec 2013 --> Jun 2015
- Trial primary completion date: Volunteers Adding Life in Dementia (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=30, Recruiting, Sponsor: Queen's University
Trial primary completion date: Dec 2013 --> Jun 2015 Trial primary completion date: Mar 2014 --> Dec 2014
- Trial primary completion date: PC-DATA: The Primary Care - Dementia Assessment and Treatment Algorithm (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=135, Recruiting, Sponsor: Queen's University
Trial primary completion date: Mar 2014 --> Dec 2014 Trial primary completion date: Mar 2014 --> Mar 2015
- Biomarker, Enrollment change, Trial primary completion date: Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=1000, Recruiting, Sponsor: Minneapolis Medical Research Foundation
Trial primary completion date: Mar 2014 --> Mar 2015 N=300 --> 1000 | Trial primary completion date: Aug 2014 --> Aug 2015
- Clinical: The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=29, Completed, Sponsor: Mentis Cura
- Enrollment open: Actigraphy to MEasuRe Intensive Care Unit Activity (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=75, Recruiting, Sponsor: Vanderbilt University
N=300 --> 1000 | Trial primary completion date: Aug 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- | Biomarker, Trial completion: Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=16, Completed, Sponsor: KineMed
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=0, Withdrawn, Sponsor: Avid Radiopharmaceuticals
Active, not recruiting --> Completed N=10 --> 0 | Not yet recruiting --> Withdrawn
- || isoflurane / Generic mfg.
Trial primary completion date: MAD-PIA: Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia (clinicaltrials.gov) - Oct 23, 2014
P1, N=100, Recruiting, Sponsor: Duke University
N=10 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Mar 2014 --> Mar 2015
- OMS824 / Omeros
Trial suspension: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Oct 22, 2014
P2, N=36, Suspended, Sponsor: Omeros Corporation
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Suspended
- ||| Clinical: IGF and Other Neurotrophic Factors in Patients With Dementia (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: University of Aarhus
- Enrollment open: Exploratory Study for the Validity of QuQu Scale (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=400, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Trial completion, Enrollment change, Trial primary completion date: Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment (HM2) (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=44, Completed, Sponsor: Parkwood Hospital, London, Ontario
Not yet recruiting --> Recruiting Recruiting --> Completed | N=126 --> 44 | Trial primary completion date: Aug 2013 --> Nov 2013
- donepezil / Generic mfg.
Biomarker, Trial completion: Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development (clinicaltrials.gov) - Oct 22, 2014
P1, N=30, Completed, Sponsor: University Hospital, Lille
Recruiting --> Completed | N=126 --> 44 | Trial primary completion date: Aug 2013 --> Nov 2013 Recruiting --> Completed
- |||| LMTX (hydromethylthionine) / TauRx
Enrollment status: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - Oct 21, 2014
P3, N=700, Recruiting, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed Recruiting --> Recruiting
- Clinical: Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=30, Recruiting, Sponsor: Ohio State University
- || Trial primary completion date: PreDeLight-ICU: Prevention of Delirium With Light in the Intensive Care Unit (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=96, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Nov 2016
- donepezil / Generic mfg.
Trial primary completion date: Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB) (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=40, Recruiting, Sponsor: Osaka University
Trial primary completion date: Nov 2014 --> Nov 2016 Trial primary completion date: Aug 2014 --> Feb 2015
- Enrollment change, Trial termination, Trial primary completion date: pré MATAPA: Alzheimer Disease : Rehabilitation's Intervention at Home (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=17, Terminated, Sponsor: Nantes University Hospital
Trial primary completion date: Aug 2014 --> Feb 2015 N=30 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> May 2014; difficulties of recruitment
- ||| HEOR: Behavioral Interventions to Prevent or Delay Dementia (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=600, Recruiting, Sponsor: Mayo Clinic
- ||| Clinical: Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=322, Completed, Sponsor: Aristotle University Of Thessaloniki
- | dexmedetomidine / Generic mfg.
Surgery: Dexmedetomidine and Delirium in Patients After Cardiac Surgery (clinicaltrials.gov) - Oct 17, 2014
P4, N=284, Not yet recruiting, Sponsor: Peking University First Hospital
- | buprenorphine transdermal / Generic mfg., paracetamol / Generic mfg.
New P4 trial: DEP-PAIN-DEM: Efficacy of Pain Treatment on Depression in Patients With Dementia (clinicaltrials.gov) - Oct 17, 2014
P4, N=266, Recruiting, Sponsor: University of Bergen
- sevoflurane / Generic mfg.
Clinical: POCD-MRI: Cohort Study to Investigate the Association Between Changes in Brain Volume and Postoperative Cognitive Dysfunction (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=100, Recruiting, Sponsor: Nicolai Goettel
N=30 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> May 2014; difficulties of recruitment Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- Trial completion, Trial primary completion date: MACAP: Capacity Assessment in Persons With Alzheimer's Disease (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=400, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- Clinical: Deep Brain Stimulation for Patients With Dementia With Lewy Bodies (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=6, Recruiting, Sponsor: University College, London
- ||| donepezil / Generic mfg.
Clinical: A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS) (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=700, Recruiting, Sponsor: Eisai Korea Inc.
- Clinical: LESCOD: "Lewy Body Screening in Cognitive Disorders" (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=180, Not yet recruiting, Sponsor: Nantes University Hospital
- blarcamesine (Anavex 2-73) / Anavex
Phase classification, PK/PD data: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Oct 11, 2014
P2, N=32, Not yet recruiting, Sponsor: Anavex Life Sciences Corp.
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Phase classification: P2a --> P2
- ||| Clinical: EXDEM: Effects of an Exercise Program for Nursing Home Patients With Dementia (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=170, Recruiting, Sponsor: Oslo University College
- ||||| landipirdine (SYN120) / Acorda
New P2 trial: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Oct 10, 2014
P2, N=80, Not yet recruiting, Sponsor: Biotie Therapies Inc.
- ||||| atabecestat (JNJ-54861911) / J&J
New P2 trial: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Oct 10, 2014
P2, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Enrollment open: Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=360, Recruiting, Sponsor: Enzymotec
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting
- AADvac1 / Axon Neurosci
Enrollment closed, Trial primary completion date: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (clinicaltrials.gov) - Oct 10, 2014
P1, N=30, Active, not recruiting, Sponsor: Axon Neuroscience SE
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015
- Trial completion: Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI) (clinicaltrials.gov) - Oct 10, 2014
P1, N=60, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Completed
- || PF-05212377 / Pfizer
Trial primary completion date: Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil (clinicaltrials.gov) - Oct 4, 2014
P2, N=342, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Trial primary completion date: Jan 2016 --> May 2016
- |||| PF-02545920 / Pfizer
Enrollment open, Trial primary completion date: Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease (clinicaltrials.gov) - Oct 4, 2014
P2, N=260, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2016 --> May 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
Enrollment open: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Oct 2, 2014
P2, N=10, Recruiting, Sponsor: Sheppard Pratt Health System
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016 Not yet recruiting --> Recruiting